Latest Incentive Payments News

Praemium plans a staged rollout of its new core technology platform this year, following the integration of Technotia Laboratories. The company has restructured its tech team to cut costs and revised incentive payments for two founding Technotia principals transitioning to consulting roles.

Green Cross Health lifted net profit by 28% to NZD 20.4 million in FY26, driven by stronger medical funding and pharmacy revenue growth, while preparing to launch a new Primary Health Organisation.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Advanced Braking Technology Ltd reports a robust Q2 FY26 with a 34% increase in product sales revenue and a 191% jump in net profit before tax, underpinned by strong international expansion and domestic contract wins.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.

TerraCom Limited reports a $43.4 million net loss for FY25, reflecting increased impairment charges and operational challenges, while advancing its strategic Moorlands Project in Australia.

Iress Limited has appointed Andrew Russell as its new Group CEO, marking a strategic leadership shift following a major company transformation. Russell’s extensive fintech experience positions him to lead Iress into a product and client-focused future.

Praemium Limited reported robust FY25 results with revenue climbing 24.6% to $103 million and net profit after tax soaring 55% to $13.56 million, underpinned by strong growth in funds under administration and strategic product launches.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million in FY25 but saw an 8.1% decline in underlying net profit after tax to $27.4 million, impacted by market softness and operational incidents. The company outlines cautious FY26 guidance amid ongoing sector headwinds.

Austal Limited has finalized a Strategic Shipbuilding Agreement with the Commonwealth of Australia, positioning its subsidiary as the nation’s key Tier 2 naval shipbuilder. This long-term pact sets the stage for significant defence vessel construction in Western Australia.